

A WORLD OF SOLUTIONS

ABMC

**American Bio Medica Corporation
Annual Meeting of Shareholders
June 16, 2009**

ABMC®

AMERICAN BIO MEDICA
CORPORATION

A WORLD OF SOLUTIONS



American Bio Medica Corporation (NASDAQ:ABMC)

This presentation may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development, regulatory approvals and intellectual property rights, and the Company's dependence on key personnel and third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2008, and quarterly reports on Form 10-Q on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

ABMC Facilities & Certifications

- Two FDA compliant facilities
- ISO 13485:2003 Certified & ISO 9001:2000 Certified
- CLIA waived Rapid TOX® product line
- FDA 510(k) Cleared products
 - Exception: OralStat® and Rapid STAT™
- CE Marked products
 - Rapid TOX Cup® II in process

A WORLD OF SOLUTIONS

ABMC

Corporate Office Administration, Assembly & Packaging/Warehouse Kinderhook, New York

Front Lobby



Assembly



Warehouse



A WORLD OF SOLUTIONS



Laboratory Facility

R&D, Strip Production, Contract Manufacturing
Logan Township, New Jersey

Various laboratories & strip production



A WORLD OF SOLUTIONS

ABMC

ABMC Products



Intellectual Property as of December 31, 2008


- 26 US and International patents issued
- 16 Patents pending
 - 8 US & 8 International

Established Product Performance

- > 99% correlation to GC/MS
- Department of Health and Human Services Study
 - Top multi-panel device for overall accuracy
 - 99% correlation to EMIT
- ROSITA Study
 - Finished with the highest score for ease of use
 - No other device finished more accurate

Most Accurate in the Industry

(according to DHHS study of POCT Devices)



- ABMC submitted Rapid Drug Screen® for this study
- 13 other products evaluated

Product Portfolio & Cross Reactivity

- Largest point of collection drug testing portfolio in the industry
 - Most extensive options for testing configurations
- Cross reactivity information on over 600 OTC and prescription medications

Drug	Abbrev	Detection Level (ng/ml)
Amphetamines	AMP	1000
Barbiturates	BAR	300
Buprenorphine	BUP	12.5
Cannabinoids	THC	50
Cocaine	COC	300 or 150
Ecstasy	MDMA	1000
Methadone	MTD	300
Methamphetamines	METH	1000
Opiates	OPI	300 or 2000
Oxycodone	OXY	100
Phencyclidine	PCP	25
Propoxyphene	PPX	300
Tricyclic Antidepressants	TCA	1000

Rapid Drug Screen Core Product





- Multiple drug test platform
- Screens for 2-10 drugs simultaneously
- Results in 3-5 minutes
- Customized configurations available
- Colloidal Gold Technology (superior sensitivity, accuracy and precision)

Rapid ONE®

Expansion of RDS Product Line to Meet Specific Market Needs

- Single drug test for use when specific drug abuse is suspected
- Available for 13 different drugs of abuse (and 2 different cutoff levels for cocaine and opiates)
- Transition from dipstick to cassette platform (to enable automation)



OralStat

Oral Fluid Test for Drugs of Abuse




- Convenience of point of collection with the sensitivity, accuracy & precision of lab test
- Specimen adulteration or dilution is virtually eliminated
- No restroom required
- Eliminates gender issues with observed collections
- Detects parent THC
- Multiple configurations available



10 panel OralStat!

- Available beginning Q2 2009
- ABMC is first company to offer a 10 panel oral fluid product
- Provides customers with even more testing flexibility



RDS® InCup® One Step All Inclusive Cup



- Multiple drug platform
- Screens for 2-12 drugs simultaneously using single strip assays
- Incorporates collection and testing in less than 5 minutes
- Closed specimen cup-no exposure

Rapid TOX


Cost Effective Cassette Platform



- Cost effective cassette platform
- Screens for 2-10 drugs simultaneously
- Can either be dipped in urine specimen or specimen can be pipetted (dropped) onto cassette
- Customization available
- CLIA waiver granted by FDA in August 2008

Rapid Reader®

All Inclusive Drug Screen Interpretation & Data Management System



- PC peripheral device; USB powered & connected
- Scan, interprets, records, transmits and stores results of ABMC drug tests
- Virtually eliminates test interpretation errors
- Reduces costs by reducing confirmations
- 510(k) Cleared by Food and Drug Administration

Rapid STAT


Oral Fluid test for drugs of abuse

point of collection testing with speed and portability




- Sample handling procedure maximizes drug recovery for testing
- Provides transport container for confirmation of positive results
- Faster test results and portability make it ideal for roadside testing
- Lower THC (marijuana) testing sensitivity, making it unrivaled in the market

Rapid TOX Cup II Cost Effective All Inclusive Cup




- New design offered beginning Q1 2009
- Incorporates collection and testing of up to 10 drugs simultaneously in just minutes
- Multi-strip format = more cost effective for ABMC customers
- Specimen can be sent in same container for confirmation of positive results

Current Business/Market Segments




ABMC Sales



Market Segment Detail

Significant components FYE 2008



Note: Workplace market includes National Account sales

Year to date 2008 News in Review

- ABMC TO MANUFACTURE TEST FOR SYPHILIS for Hema Diagnostic Systems
- ABMC ANNOUNCES NEW BOARD APPOINTMENT- Jean Neff, former Sr. Vice President of Laboratory Corporation of America
- ABMC SIGNS MASTER DISTRIBUTION AGREEMENT WITH DEVOR GLOBAL covering Latin America, including South America
- ABMC ANNOUNCES CONTRACT IN THE DOMINICAN REPUBLIC- Exclusive Contract with the National Network of Transportation
- ABMC SUPPLIES SAVE MART SUPERMARKETS WITH ORAL FLUID DEVICES
- ABMC COMPLETES SERIES A DEBENTURE FINANCING
- FDA GRANTS CLIA WAIVER TO ABMC FOR ITS RAPID TOX
- ABMC RAPID STAT TO BE USED BY THE FRENCH MINISTRY OF INTERIOR

ABMC Going Forward Clinical Partner

- CLIA waiver could have positive impact on clinical market
 - Currently in discussions with a potential global distributor

ABMC Going Forward Laboratory Alliance

Purchase Agreement with one of the world's largest clinical labs

- S&P 500 listed company
- Laboratory will purchase ABMC tests for use in locations located strategically throughout the United States
- Sales in 2008 and so far in 2009 have been negatively impacted by global economic crisis


ABMC Going Forward CLIA waived markets

- Expect Laboratory Alliance to begin to use CLIA waived ABMC products in 1,600 occupational health/patient centers – transition (to date) has been delayed

ABMC Going Forward Roadside Testing

- Countries have reacted at the highest level to the possible harms posed by drugs and driving. Many countries have tightened laws, increased penalties or have altered national strategies (e.g. road safety or drug strategies) to address the problem.
- Several countries have passed laws to allow or define roadside drug testing; such as France, Italy, Germany, Poland, United Kingdom, Spain, Slovenia, Czech Republic, Latvia, Croatia, Austria, Australia, Lithuania, and Portugal. Many other countries evaluating the application of roadside testing.
- 9/4/08 – French Ministry of Interior to use ABMC products on French motorists at the roadside; 900,000 oral fluid tests over the next 3 years.
- Other contracts currently in place and additional contracts expected in 2009.

Future Business/Market Segments



ABMC's Nasdaq Capital Market Status

- October 30, 2008 – Nasdaq suspended enforcement of bid price requirement due to extraordinary conditions
- December 23, 2008 – Nasdaq extended suspension of bid price requirement
- March 27, 2009 – Nasdaq further extended suspension of bid price requirement
 - ABMC expects it will have until August 11, 2009 to regain compliance with bid price requirement (unless Nasdaq issues another suspension extension)

Status of ABMC's banking/financial position

- Company has the following credit facilities with First Niagara Financial Group (FNFG)
 - Line of Credit (LOC) - \$621,000 as of March 31, 2009
 - Term Note - \$330,000 as of March 31, 2009
 - Real Estate Mortgage - \$734,000 as of March 31, 2009
 - o Total as of March 31, 2009 - \$1,685,000
- February 4, 2009 – Notice of default received – default was related to certain financial covenants under LOC and NOT for non-payment
- March 12, 2009 – Forbearance Agreement executed – full refinancing of Line of Credit, Term Note and Mortgage required
 - Forbearance extended until June 12, 2009 to refinance LOC, and until July 1, 2009 to refinance Term Note and Mortgage
 - Company currently in document phase of LOC refinance with a bona fide third party